Anavex submits new FDA data and advances EMA dialogue on blarcamesine
Anavex continues EMA discussions to address CHMP feedback and advance oral blarcamesine’s early Alzheimer’s program in Europe while submitting additional data to the FDA to align on potential NDA pathways. The company has also initiated regulatory engagements for blarcamesine in Parkinson’s disease and Rett syndrome within EU jurisdictions.
1. Continued EMA Dialogue on Alzheimer’s
Following withdrawal of its EU marketing application, Anavex is gathering additional clinical and analytical data to address CHMP’s concerns and is in ongoing discussions with EMA to advance the oral blarcamesine program for early Alzheimer’s disease toward a potential approval pathway.
2. FDA Submission Targets NDA Alignment
Anavex has submitted new safety, biomarker, and efficacy data to the FDA to clarify regulatory requirements and align on potential NDA submission strategies for blarcamesine in early Alzheimer’s disease within the U.S. market.
3. Expanding EU Engagement for Parkinson’s and Rett
The company has initiated regulatory meetings with European authorities to explore blarcamesine’s application in Parkinson’s disease and rare neurological conditions, including Rett syndrome, reflecting the drug’s broad clinical development pipeline and potential multi-indication value.